Abstract: An acoustic output of therapeutic devices used in shock wave therapy can be obtained by measuring the pressure waves radiated from the pressure wave transducer in water. Since the pressure waves used in shock wave therapy generate severe bubbles in water, measuring the surface vibrations of the pressure wave transducer using the laser Doppler method includes significant noise caused by the bubbles. This invention utilizes a filter generated to eliminate the noise in the vibration signals measured by the laser Doppler method, which is caused by the bubbles. The filter is generated by comparing the vibration signals measured in degassed distilled water with the reference signals measured in air at the minimum output setting of the shock wave generation device. Using the filter, it is possible to estimate the vibration signals of the pressure wave transducer generated underwater under the set conditions of the specific shock wave generating device.

Abstract: The present invention relates to a 5-membered heteroaryl derivative containing an N, and a pharmaceutical composition for use in preventing or treating mental disorders, containing same as an active ingredient, wherein the derivative is excellent in the triple reuptake inhibitory effect of serotonin, norepinephrine, and dopamine, and thus can be useful in the treatment of mental disorders.

Abstract: The present invention relates to a pharmaceutical composition comprising trimebutine as an active ingredient for prevention or treatment of cancer. Having an excellent effect of selectively inhibiting growth and proliferation of cancer stem cells, the pharmaceutical composition can suppress the recurrence, metastasis, and progression of cancer even when used alone. Thus, the composition can be advantageously used as a pharmaceutical composition for prevention or treatment of cancer or in combination with other agents.

Abstract: Provided are a posttraumatic stress disorder (PTSD) animal model in which dopamine receptor subtype 4 (D4R) is damaged or deficient, a method for preparing the same, a method for screening a drug for treating PTSD using the same, and a pharmaceutical composition for treating PTSD comprising a drug detected by the screening method. As it is identified that a specific type of dopamine receptor is associated with a mechanism for fear memory expression induced by long-term depression (LTD), the understanding of pathogenesis of PTSD may be heightened, the animal model exhibiting similar clinical conditions of PTSD and the method for preparing the same may be applied in analyses for stability and effectiveness of a therapeutic agent for PTSD and screening of a therapeutic drug. Further, an agonist of D4R contained in the composition has been approved by the US FDA and clinically used for psychiatric diseases such as schizophrenia, and thus may be immediately used for clinical applications for PTSD symptoms.

Abstract: Provided are a posttraumatic stress disorder (PTSD) animal model in which dopamine receptor subtype 4 (D4R) is damaged or deficient, a method for preparing the same, a method for screening a drug for treating PTSD using the same, and a pharmaceutical composition for treating PTSD comprising a drug detected by the screening method. As it is identified that a specific type of dopamine receptor is associated with a mechanism for fear memory expression induced by long-term depression (LTD), the understanding of pathogenesis of PTSD may be heightened, the animal model exhibiting similar clinical conditions of PTSD and the method for preparing the same may be applied in analyses for stability and effectiveness of a therapeutic agent for PTSD and screening of a therapeutic drug. Further, an agonist of D4R contained in the composition has been approved by the US FDA and clinically used for psychiatric diseases such as schizophrenia, and thus may be immediately used for clinical applications for PTSD symptoms.

Abstract: Disclosed are an oxygen barrier resin composition and products containing the resin. The resin composition comprises 20 to 80 wt % of an ethylene-vinyl alcohol copolymer, 5 to 79 wt % of an ethylene copolymer, and 1 to 30 wt % of a compatibilizer obtained between a random copolymer of ethylene-maleic anhydride-alkyl(meth)acrylate and a polyamide oligomer ranging, in molecular weight, from 1,000 to 5,000. The compatibilizer functions in such a way that the main chain of the polyamide penetrates into the ethylene-vinyl alcohol phase while the main chain of the ethylene-alkyl(meth)acrylate exists in the ethylene copolymer phase. The resin composition is superior in both melt-moldability and compatibility, providing films, sheets or bottles with superb appearance (transparency), mechanical strength and oxygen barrier.